LTRN vs. ASMB, LABP, DERM, SCYX, VHAQ, YS, RLYB, MNOV, IFRX, and MURA
Should you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include Assembly Biosciences (ASMB), Landos Biopharma (LABP), Journey Medical (DERM), SCYNEXIS (SCYX), Viveon Health Acquisition (VHAQ), YS Biopharma (YS), Rallybio (RLYB), MediciNova (MNOV), InflaRx (IFRX), and Mural Oncology (MURA). These companies are all part of the "pharmaceutical preparations" industry.
Lantern Pharma (NASDAQ:LTRN) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, community ranking, analyst recommendations and profitability.
Assembly Biosciences received 230 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 75.00% of users gave Lantern Pharma an outperform vote while only 59.31% of users gave Assembly Biosciences an outperform vote.
Lantern Pharma has higher earnings, but lower revenue than Assembly Biosciences.
28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 6.9% of Lantern Pharma shares are owned by company insiders. Comparatively, 5.1% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Assembly Biosciences had 23 more articles in the media than Lantern Pharma. MarketBeat recorded 28 mentions for Assembly Biosciences and 5 mentions for Lantern Pharma. Assembly Biosciences' average media sentiment score of 0.14 beat Lantern Pharma's score of 0.02 indicating that Assembly Biosciences is being referred to more favorably in the news media.
Lantern Pharma's return on equity of -39.09% beat Assembly Biosciences' return on equity.
Lantern Pharma has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.
Summary
Lantern Pharma beats Assembly Biosciences on 7 of the 11 factors compared between the two stocks.
Get Lantern Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lantern Pharma Competitors List
Related Companies and Tools
